Charles A. Rowland's Insider Trades & SAST Disclosures
Charles A. Rowland's most recent trade in Viking Therapeutics Inc was a trade of 18,800 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Charles A. Rowland.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 18,800 | 18,800 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | A. Charles Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Rowland Charles A. | Director | Purchase of securities on an exchange or from another person at price $ 1.31 per share. | 01 Dec 2023 | 192,960 | 384,757 | - | 1.3 | 252,778 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 1.50 per share. | 01 Dec 2023 | 150,000 | 534,757 | - | 1.5 | 225,000 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 16 May 2023 | 40,000 | 70,000 (0%) | 0% | 1.1 | 43,200 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 May 2023 | 40,000 | 30,000 (0%) | 0% | 25 | 1,000,000 | Common Stock, par value $0.00001 per share |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.26 per share. | 19 Sep 2022 | 15,750 | 191,797 | - | 5.3 | 82,845 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.48 per share. | 15 Sep 2022 | 33,481 | 176,047 | - | 5.5 | 183,476 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.41 per share. | 15 Sep 2022 | 17,147 | 142,566 | - | 5.4 | 92,765 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 13 Sep 2022 | 18,784 | 119,819 | - | 5.2 | 97,752 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 5.30 per share. | 13 Sep 2022 | 5,600 | 125,419 | - | 5.3 | 29,652 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,200 | 19,200 | - | - | Stock Option (right to buy) | |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,250 | 5,812 (0%) | 0% | 0 | Common Stock | |
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 24.50 per share. | 11 Jan 2021 | 20,408 | 101,035 | - | 24.5 | 499,996 | Common Stock |
| Viking Therapeutics Inc | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 117.82 per share. | 17 Dec 2020 | 10,909 | 3,562 (0%) | 0% | 117.8 | 1,285,298 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 10,909 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.53 per share. | 17 Dec 2020 | 10,909 | 14,471 (0%) | 0% | 19.5 | 213,053 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 5,522 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.46 per share. | 02 Nov 2020 | 5,522 | 9,084 (0%) | 0% | 9.5 | 52,238 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 99.10 per share. | 02 Nov 2020 | 4,728 | 4,256 (0%) | 0% | 99.1 | 468,545 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 99.11 per share. | 02 Nov 2020 | 4,478 | 3,562 (0%) | 0% | 99.1 | 443,815 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 4,478 | 5,522 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.46 per share. | 02 Nov 2020 | 4,478 | 8,040 (0%) | 0% | 9.5 | 42,362 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 95.97 per share. | 02 Nov 2020 | 694 | 3,562 (0%) | 0% | 96.0 | 66,603 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Sale of securities on an exchange or to another person at price $ 100.48 per share. | 02 Nov 2020 | 100 | 8,984 (0%) | 0% | 100.5 | 10,048 | Common Stock |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 4,500 | 4,500 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2020 | 2,250 | 3,562 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 1,312 | 1,312 (0%) | 0% | - | Common Stock | |
| Blueprint Medicines Corp | Charles A. Rowland | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 1,312 | 0 | - | - | Restricted Stock Units | |
| Generation Bio Co | Charles A. Rowland | Director | 16 Jun 2020 | 89,423 | 0 | - | - | Series C Preferred Stock | ||
| Generation Bio Co | Charles A. Rowland | Director | 16 Jun 2020 | 50,627 | 50,627 | - | - | Common Stock | ||
| Generation Bio Co | Charles A. Rowland | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 16 Jun 2020 | 30,000 | 80,627 | - | 19 | 570,000 | Common Stock |
| Generation Bio Co | Charles A. Rowland | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 52,000 | 52,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges